The new calcium channel blocker azelnidipine found to have an added effect on Olmesartan action on  hypertensive diabetic patients, has an advantage in chronic kidney patients. Here is the study.

  Team@CMHF

These results suggest that the addition of azelnidipine to the maximal recommended dose of olmesartan was more effective in reducing albuminuria and oxidant stress in hypertensive diabetic patients with CKD than the addition of amlodipine.

Methods

• Authors conducted an open–label, randomized, parallel–controlled study on type 2 diabetic patients with stable glycemic control who were receiving fixed doses of antidiabetic agents.
• The patients received either 8mg per day azelnidipine, which was increased up to 16mg per day, or 2.5mg per day amlodipine, which was increased up to 5mg per day, over a 24–week period.

Results

• Mean systolic and diastolic blood pressure decreased significantly in both groups, but there was no significant difference between the two groups at the end of the study.
• Serum creatinine levels and estimated glomerular filtration rate did not differ significantly between the two groups, whereas the urinary albumin/creatinine ratio and 8–OHdG and L–FABP levels decreased significantly in the azelnidipine group compared with the amlodipine group.
• Plasma aldosterone level was significantly decreased in the azelnidipine group, and its changes correlated

Ref: http://www.mdlinx.com/family-medicine/xml-article.cfm/3639455